Destiny Pharma plc, of Brighton, U.K., said its lead clinical candidate, exeporfinium chloride (XF-73), has been granted fast track designation by the FDA for the prevention of postsurgical staphylococcal infections such as methicillin resistant Staphylococcus aureus.